68 Ga-DOTATOC Pictorial Essay of Various Recurrent Meningiomas Rejected for Treatment With 177 Lu-DOTATATE : Is There a Place for Another Theranostic Examination?
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 38689436.
- Also identified by DOI 10.1097/RLU.0000000000005247.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the cases of 4 patients treated for recurrent meningiomas of various grades. Pretreatment 68 Ga-DOTATOC PET/CT was performed prior to screening for vectorized internal radiotherapy with 177 Lu-DOTATATE or prior external radiotherapy to aid contouring. None of these patients had sufficient uptake to be eligible for 177 Lu-DOTATATE or reliable contouring. Most recurrences were grades II and III, suggesting a loss of physiological somatostatin receptor overexpression in these tumors. Therefore, the benefit of treatment with 177 Lu-DOTATATE in the current indication is questionable. In the absence of a validated systemic treatment, and considering a few case reports, treatment with 177 Lu-PSMA could be investigated as an additional vectorized internal radiotherapy option.
Medical subject headings
- Meningioma
- Octreotide
- Organometallic Compounds
- Positron Emission Tomography Computed Tomography